Biognosys

What Biognosys does

Biognosys is a Swiss proteomics company, majority-owned by Bruker Corporation since January 2023, that provides next-generation proteomics solutions spanning contract research services, analytical software, and consumable kits to pharmaceutical, biotechnology, and academic customers. Its core technology combines Data Independent Acquisition (DIA) and Data Dependent Acquisition (DDA) mass spectrometry with proprietary Hyper Reaction Monitoring (HRM) methods and the P2 Plasma Enrichment workflow, enabling unbiased quantification of up to ~4,200 proteins in plasma, ~11,000 in biofluids, and ~13,800 in tissue or cell lines. The product portfolio centers on Spectronaut, a vendor-agnostic DIA proteomics software platform that also powers the TrueDiscovery, TrueTarget, and TrueSignature CRO service platforms, complemented by SpectroMine (DDA), SpectroDive (targeted), QuiC (free QC), OmicsFlow (automated sample processing), and peptide kits such as PQ500, iRT, and P2-iST.

The company monetizes through three primary streams: (1) CRO services delivered via direct enterprise sales to pharma and biotech clients for biomarker discovery, drug target validation, and clinical-trial pharmacoproteomics, sold on a project/multi-year basis with optional GLP/GCP compliance; (2) software licensing of Spectronaut and related products on both annual subscription and perpetual-plus-maintenance terms, distributed direct and through a reselling agreement with Thermo Fisher Scientific; and (3) consumable kits and reagents for in-house proteomics workflows, sold through the company website, a global distributor network, and, since 2024, NULISA assays from Alamar Biosciences. Distribution is anchored by the Bruker timsTOF partnership (giving preferred access to 4D-proteomics instruments), Thermo Fisher reselling, and US operations based in Newton, Massachusetts. The company is led by Co-Founder and CEO Dr. Oliver Rinner and reports a global footprint with 51-100 employees across Schlieren (Switzerland) and Newton, Massachusetts.

Name

Biognosys

Legal name

Biognosys AG

Website

https://biognosys.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Biognosys is a Swiss proteomics company (majority-owned by Bruker) that provides DIA mass spectrometry CRO services, Spectronaut software, and peptide kits to pharmaceutical, biotech, and academic customers for biomarker discovery, drug development, and clinical research.

Ownership category

akta.pro rank

Product category

Proteomics Software

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Proteomics & Mass Spectrometry Services (HLAGANAB)

akta.pro secondary industries

Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Proteomics & Biomarker Analytical Testing (HLAGADAG), Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD)

Keywords

• Proteomics software solutions
• Mass spectrometry analysis
• Biomarker discovery services
• Contract research organization
• Protein quantification tools

Headquarters

HQ city

Schlieren

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. CRO Services: Contract research organization services providing proteomics analysis for pharma and biotech clients including TrueDiscovery, TrueTarget, and TrueSignature platforms. Services include biomarker discovery, drug discovery, and pharmacoproteomics for clinical trials.
2. Software Licensing: Licensing of Spectronaut, SpectroMine, SpectroDive, and QuiC software for proteomics data analysis. Available as recurring licenses or perpetual licenses with annual maintenance fees.
3. Kits and Reagents: Sale of peptide kits including PQ500 reference peptides for quantification, iRT kits for quality control, and sample preparation reagents for researchers conducting proteomics in-house.
4. Method Transfer: Transfer of proprietary P2 Plasma Enrichment workflow to customers who wish to conduct the method in-house, including documentation, training, and initial materials.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Biognosys develops and commercializes next-generation proteomics solutions comprising proprietary software platforms (Spectronaut, SpectroMine, SpectroDive, QuiC, OmicsFlow, Proteoverse) for mass spectrometry-based protein analysis, contract research organization services (TrueDiscovery, TrueTarget, TrueSignature) for biomarker discovery and drug target identification, and consumable peptide/reagent kits (PQ500 Reference Peptides, iRT Kit, P2 Plasma Enrichment, P2-iST) for sample preparation and assay calibration.

Product overview

Biognosys offers an integrated proteomics portfolio consisting of software products (Spectronaut® for DIA proteomics, SpectroMine™ for DDA proteomics, SpectroDive™ for targeted proteomics, QuiC™ for QC, OmicsFlow® for automated processing), peptide kits (PQ500™ Reference Peptides, iRT Kit, P2-iST), proprietary technologies (P2 Plasma Enrichment), and research service platforms (TrueDiscovery®, TrueTarget™, TrueSignature™). The software products form the analytical foundation, with Spectronaut serving as the core DIA platform that also powers the TrueDiscovery CRO services. The kit products enable researchers to perform proteomics in-house, while CRO services provide outsourced proteomics research capabilities. A partnership with Bruker enables integration with timsTOF mass spectrometry platforms and metabolomics services.

Differentiator

Problem solved

Functional benefit

Brands

• Spectronaut®: Vendor-agnostic software for DIA (Data Independent Acquisition) proteomics analysis, the leading software for next-generation proteomics.
• SpectroMine™
• SpectroDive™
• QuiC™
• OmicsFlow®
• TrueDiscovery®
• TrueTarget™
• TrueSignature™
• PQ500™
• Proteoverse®
• P2 Plasma Enrichment
• iRT Kit
• NULISA™

Products and services

• Spectronaut Flagship DIA proteomics analysis software for protein identification, quantification, and statistical analysis of mass spectrometry data, used by pharma, biotech, and academic researchers worldwide.
• SpectroMine DDA proteomics analysis software for protein identification and quantification from mass spectrometry data, supporting spectral library generation and routine discovery workflows.
• SpectroDive Targeted proteomics software for reproducible, high-throughput quantification of proteins and peptides using targeted mass spectrometry assays (e.g., PRM/SRM).
• QuiC Quality control software for monitoring and assessing the quality of mass spectrometry-based proteomics experiments.
• OmicsFlow Automated proteomics workflow software that orchestrates and streamlines multi-step data analysis pipelines for routine and high-throughput proteomics.
• Proteoverse Digital proteome data platform for managing, sharing, and exploring proteomics datasets across teams and projects.
• TrueDiscovery Contract research service providing unbiased, deep proteome profiling and biomarker discovery using Biognosys's DIA workflows and software, delivered to pharma, biotech, and academic customers.
• TrueTarget Contract research service for drug target identification and deconvolution using chemical proteomics and affinity-based mass spectrometry workflows.
• TrueSignature Contract research service for the development and validation of targeted biomarker signature panels using targeted mass spectrometry assays.
• PQ500 Reference Peptides Quantitative reference peptide kit providing internal standards for absolute and relative quantification in targeted mass spectrometry proteomics assays.
• iRT Kit Indexed Retention Time (iRT) reference peptide kit used for retention time calibration and scheduling in mass spectrometry proteomics experiments.
• P2 Plasma Enrichment Plasma sample preparation kit enabling high-throughput, reproducible plasma proteomics workflows for biomarker research.
• P2-iST Integrated sample preparation kit (P2-iST) for streamlined and reproducible proteomics sample processing workflows.

Quantifiable outcome

• 10% more protein groups and 11% more peptides identified with Spectronaut 21
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature12 records

Partnerships

Six partnerships are on record, tiered core and major.

• SISCAPA Assay TechnologiescoreStrategic or Co-development Partner · 12 June 2026Collaboration to develop ultra-sensitive targeted protein assays for clinical research. Biognosys uses its SISCAPA and TrueSignature targeted proteomics platforms to create assays for deployment in clinical trials providing pharmacodynamic readouts.
• Biocrates Life Sciences AGmajorStrategic or Co-development Partner · 12 June 2026Partnership to expand hybrid metabolomics offerings. Biognosys launched metabolomics/lipidomics services using Biocrates technology to complement its proteomics capabilities for multiomic drug discovery.
• The Michael J. Fox Foundation for Parkinson's ResearchcoreStrategic or Co-development Partner · 15 April 2026Collaboration to develop sensitive and quantitative biomarker assays for LRRK2, the most common genetic risk factor for late-onset Parkinson's disease. Supports MJFF's LITE initiative involving more than 50 academic, industry, and clinical partners using open-science approach.
• FreenomecoreStrategic or Co-development Partner · 18 March 2026Partnership to combine Biognosys' protein quantification capabilities with Freenome's AI genomics platform for early-cancer detection and precision oncology. Integrates protein and cell-free DNA/RNA analysis for improved multi-analyte screening.
• Thermo Fisher ScientificmajorChannel Partner/ Reseller/ Distributor · 1 September 2024Reselling agreement for Spectronaut proteomics software, making it directly available from Thermo Fisher Scientific alongside their mass spectrometry systems.
• Alamar BiosciencesmajorStrategic or Co-development Partner · 1 January 2024Strategic partnership to expand Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomics. NULISA assays now commercially available through Biognosys.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Thermo Fisher Scientific: Global mass spectrometry and life sciences instrument leader that resells Spectronaut and offers its own proteomics analysis pipelines. Comparable as both a distribution partner and a potential competitor for DIA software and proteomics services.
• Bruker Corporation: Biognosys' majority owner and timsTOF mass spectrometry platform provider. Operates broadly across proteomics instruments and 4D-proteomics workflows that directly underpin Biognosys' discovery services.

Direct peers

• Olink Holding: Provides proteomics biomarker discovery platforms (Proximity Extension Assay) targeting pharma/biotech translational research. Directly comparable in biomarker-focused proteomics services for clinical and discovery applications.
• SomaLogic (now part of Standard BioTools): Operates the SomaScan proteomics platform for large-scale biomarker discovery serving pharma and academic customers. Directly comparable as a high-throughput proteomics services and biomarker discovery competitor.
• PreOmics: Sample-preparation technology provider for mass spectrometry-based proteomics (iST kits), previously a codefendant with Biognosys in patent challenges. Directly comparable as a proteomics workflow reagent company serving the same MS-based research market.
• Alamar Biosciences: NULISA ultra-sensitive proteomics assay developer partnered with Biognosys for distribution. Comparable as an emerging proteomics biomarker assay company targeting biopharma translational and clinical research customers.

Emerging players

• Seer: Developer of the Proteograph next-generation proteomics platform using nanoparticle-based enrichment. Comparable as an emerging proteomics technology provider pursuing unbiased deep proteome profiling for biomarker and translational research.
• Evosep: Develops standardized LC-MS workflows for high-throughput proteomics. Comparable as a workflow technology provider enabling large-scale clinical proteomics, frequently used alongside DIA pipelines similar to Spectronaut.
• Quantum-Si: Developer of next-generation single-molecule protein sequencing technology aimed at proteomics research and biomarker discovery. Comparable as an emerging player pursuing deeper proteome coverage at scale.

Others

• Cell Signaling Technology: Major provider of antibodies and proteomics reagents serving the same MS-based and antibody-based research market. Comparable as an adjacent reagent/assay vendor with strong pharma/biotech relationships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/biognosys
• YouTubeyoutube.com/channel/UC2q-Df_xpbCMapILAiwI6Rg
• LinkedInlinkedin.com/company/222049
• Facebookfacebook.com/198383770189994

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds8 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biognosys